Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OPT Group
South Yarra, Victoria, Australiaoptgroup.ai ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Opthea’s lead candidate, sozinibercept (OPT-302), is a first-in-class VEGF-C/D ‘trap’ inhibitor designed for use with standard anti–VEGF-A therapies. In Phase 2b, it showed superior visual outcomes versus standard of care. Two pivotal Phase 3 trials are fully enrolled with topline results expected in Q2 and mid 2025[1][6]. No commercial products yet.
- Therapeutic areas
- Ophthalmology
- Modalities
- Recombinant fusion proteinBiologic
- Industry
- Biotech
02
Partnerships
No major pharmaceutical partnerships disclosed; collaborates with research institutions for clinical development[4].
Beyond the preview
Go deeper on OPT Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPT Group.